UnknownPhase 3NCT02423837

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma

Studying Follicular lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Research Center for Hematology, Russia
Principal Investigator
Sergey K Kravchenko, MD, PhD
National Research Center for Hematology
Intervention
Rituximab, bendamustine(drug)
Enrollment
200 enrolled
Eligibility
18-75 years · All sexes
Timeline
2013 – 2021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02423837 on ClinicalTrials.gov

Other trials for Follicular lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Follicular lymphoma →

← Back to all trials